Happy to share our new paper on suicidal ideation in the context of PTSD "Which PTSD clusters and symptoms are central to reducing suicidal ideation? A network and cross-lagged analysis among individuals receiving cognitive processing therapy"

RT @RCarhartHarris: Extremely excited about this stellar work and new measure from @RickZeifman and co. The 'REB-Q' has a great future: "Fr…

Excited about our study examining psilocybin-assisted massed cognitive processing therapy for posttraumatic stress disorder with @shakilameshkat @KatieSPsych @CandiceMonson @venkatbhat @Dr_VenkatBhat @rakeshjetly Protocol paper now available at @PLOSONE

Excited to share this paper led by Broc Pagni Multidimensional Personality Changes Following Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Results From a Double-Blind, Placebo-Controlled Clinical Trial | American Journal of Psychiatry

Excited to get to share this pre-print/findings!

@hannahmdouglass Congratulations @hannahmdouglass !!

I'm grateful to have received this award from @nyulangone @NYULH_postdocs

Psilocybin-assisted psychotherapy improves psychiatric symptoms across multiple dimensions in patients with cancer Grateful to collaborate on this paper led by @PPetridisMD

RT @HCPLiveNews: Lastly, Alexandra Gordon of @nyulangone describes the promising clinical effect of psychedelics for the treatment of perso…

@trpwolff Interesting for sure. I wasn't involved in the primary outcomes paper where depression was the primary outcome but given the very small sample and psychotherapeutic framing of the treatment it seems understandable. Looking forward to hearing about what you found in yours!

@trpwolff It wasn't a focus unfortunately and MEQ didn't correlate with the depression outcome. A few ongoing studies with the APEQ, so will look forward to testing out link between acute states and changes in traits. Will be sure to reference and will try to invite you to explore with us!

@trpwolff An (embarrassing) oversight to not have mentioned this or cited your work. Apologies! We’ve got further support for this that we are close to submitting where we definitely do make reference to it.

@MarkLRuffalo @trpwolff @EikoFried @tkaiser_science I don't think it's helpful to think of most psychiatric disorders as diseases. That aside (and the many limitations with psychedelic research), IF psychedelic therapy does have effects that last weeks-months post-administration, would that qualify as disease-modifying?

@BWe1ss Thanks Brandon!

I'm a little late to it, but happy to share this (brief) paper where we highlight some potential methodological concerns in psychedelic research, including possible non-equivalence of therapy duration/quality and issues with generalizability

Exciting to see @MarrocuAlessia's paper on predictors of worsened mental health following psychedelic use published! Grateful for the opportunity to collaborate with @MarrocuAlessia, @KettnerHannes, @DavidErritzoe, @BWe1ss, and @RCarhartHarris on this.

@RCarhartHarris It would be great if these treatments were safe and effective without psychotherapy...but to justify the claim that an intervention does not involve psychotherapy, it seems reasonable at a minimum to ensure that your intervention is not administered by psychotherapists

RT @RCarhartHarris: Calling all folk with prior use of K, MDMA and psilocybin mushrooms. Please do this survey. We're over halfway to our t…

@MichaelHaichin One reason is that it’s helpful for reducing potential bias related to within-group effects/effects of time

Grateful to have collaborated on this paper on the effects of DMT on mental health led by @neurodelia, with @RCarhartHarris, @DavidErritzoe, and @ProfDavidNutt